Primary aldosteronism (PA), the most common cause of secondary hypertension, is a well-recognized condition that can lead to cardiovascular and renal complications. PA is frequently left undiagnosed and untreated, leading to aldosterone-specific morbidity and mortality. In this review we highlight the evidence linking PA with other conditions such as (i) diabetes mellitus, (ii) obstructive sleep apnea, and (iii) bone health, along with clinical implications and proposed underlying mechanisms.
Introduction
Despite old beliefs that primary aldosteronism (PA) is uncommon and warrants screening only when patients present with hypertension and hypokalemia, it is now believed that PA is in fact the most common cause of secondary hypertension, accounting for 5-13% of the hypertensive cohort, with an even higher prevalence among those with resistant hypertension [1, 2] . This stems from more efficient screening of this condition with the widespread use of the aldosterone:renin ratio [3, 4] . It is a disorder in which the adrenal cortex autonomously produces excessive aldosterone leading to sodium and water retention, resulting in a subsequent rise of blood pressure (BP), and the downregulation of renin through the renin-angiotensin-aldosterone system (RAAS) pathway [5] . Aldosterone-producing adenoma (APA) and bilateral hyperaldosteronism (BHA) are the most common causes of PA, with the latter being more prevalent [4, 6] . Unilateral adrenalectomy for APA can potentially cure and at least improves hypertension, and the mineralocorticoid receptor antagonist (MRA) administration for BHA effectively controls hypertension in this condition [7, 8] .
Once considered a relatively benign condition, PA has been unequivocally shown to have effects beyond its effects on BP levels [9, 10] . Hypertension alone could not explain the higher adverse cardiovascular outcomes as PA patients were found to have a higher cardiovascular mortality compared with patients with essential hypertension (EH) despite being matched for cardiovascular risks [11] . PA-directed therapy was able to reduce the excess morbidity to a level comparable to subjects with EH, regardless of the treatment modality [12, 13] . Subsequently, elevated aldosterone levels were shown to contribute to the excess morbidity and mortality [14] . Recent studies have shown that PA is associated with a myriad of other co-morbidities, particularly cardiovascular and renal injuries, which might play a role in contributing to the elevated morbidity and mortality [15] . What is less certain and less looked into is the association between PA and several nonclassical associations, namely diabetes, bone health, and sleep apnea.
Several large cardiovascular trials have suggested that the interruption of the RAAS prevented the occurrence of diabetes, raising the question of a link between PA and insulin resistance and diabetes. Besides the usual cardiovascular risk factors, obstructive sleep apnea (OSA) is known to contribute to the development of hypertension and plays an important role in resistant hypertension. There is high prevalence of OSA in resistant hypertension and it has been suggested that aldosterone is the hormone responsible for the resistant hypertension seen in this cohort of patients, although some believed it could be bidirectional [16] [17] [18] . There is also evidence that PA patients have lower bone mass leading to increased vertebral fractures which are attenuated with PA-directed therapy. Genetic studies have shown a possible relation between genes involved in PA pathway and bone strength indices [19] . Others postulated that the higher risk of osteoporosis could be contributed by cortisol excess in PA patients [20] .
Hence, the purpose of this review is to present the current evidence and understandings of the associations between PA and these nonclassically associated conditions, and discuss the clinical implications and the proposed underlying mechanisms.
PA and glucose metabolism
Human observations
PA vs EH
Fallo et al. observed a high prevalence of the metabolic syndrome in patients with PA with an elevated blood glucose level (p < 0.05), systolic BP (p < 0.01), and higher prevalence of diabetes mellitus (DM)(27.0 vs 15.2%, p < 0.05) compared with EH controls [21] . Mosso et al. also found PA patients to have higher levels of blood glucose compared with EH patients despite similar insulin levels and HOMA-IR [22] . In a retrospective case-control study, a higher prevalence of diabetes was found among those with PA (23 vs 13%, p < 0.01) despite a lower BMI [23] . Patients with PA had 26% higher risk of developing incident diabetes (HR = 1.26 [1.01, 1.57]), as well as incident mortality when compared with EH although both groups had comparable cardiovascular risk profiles and BP throughout the study [24] .
PA vs normotensive subjects
Similar prevalence rates were noted when PA patients were compared with the general normotensive population. Patients with PA had higher prevalence of type 2 diabetes (17.2 vs 10.4%, p = 0.03) and HbA1c levels (5.6 ± 0.7 vs 5.3 ± 0.8%, p < 0.01) compared with normotensive subjects [25] . In Asia, a large multicenter cohort study from Japan revealed that 21.6% of the 2210 PA population had diabetes, and this was higher than both the general population >20 years of age (12.1%), as well as 10-year cohorts aged 30-69 years [26] .
A few studies did not concur with the above findings, but the differences seen in these studies might be due in part to the small number of patients included or to the different features of the cohorts being investigated [27] [28] [29] .
Effect of treatment
Adrenalectomy led to significant increments in insulin secretion [30] , first-phase insulin reaction [31, 32] , and insulin sensitivity [33] with significant reductions in fasting [34] and 2 h plasma glucose [35] , as well as new-onset DM [36] . Two other studies, on the other hand, showed no significant differences in the fasting plasma glucose levels and glucose area under the curve during the oral glucose tolerance test postoperatively compared with preoperatively, but one study had a small sample size and the other was a retrospective study [27, 29] .
Six months to one year following the initiation of MRA therapy, there were significant increments in C-peptide (0.82 ± 0.57 to 3.32 ± 1.24 ng/dL, p < 0.001) and insulin levels (8.68 ± 5.33-13.39 ± 6.66IU/mL, p = 0.048) among 30 subjects with PA [22] . However, there were no significant changes in the plasma glucose [34] , insulin levels [33] , insulin action [31] , HOMA index [33] , and new-onset DM [36] . In fact, there seemed to be a higher incidence of impaired glucose tolerance and DM post pharmacological therapy among subjects with bilateral disease, compared with those who underwent adrenalectomy [34] . Subjects with PA on MRA, whose renin remained suppressed, similarly had higher risks for incident diabetes and cardiovascular outcomes and deaths compared with EH despite comparable BP and cardiovascular risk profiles [24] .
Summary: Two meta-analyses have strengthened the link between PA and increased prevalence of abnormal glucose metabolism [37, 38] [38] . In patients with PA, DM was noted to be more prevalent in those with bilateral disease [26, 39] , presence of positive family history of diabetes [39] , older age, higher BMI, and a higher number of antihypertensive drugs [23] . Adrenalectomy provided a more beneficial outcome in glucose metabolism compared with the use of MRA. This is believed to be due to aldosterone excess which remains significant compared with those with normalized renin on MRA or post adrenalectomy, suggesting that higher dose of MRA to normalize renin might be beneficial in reducing these risks.
Proposed mechanism
Aldosterone could have a detrimental effect on ß-cell function, leading to the occurrence of hyperglycemia. HOMA-ßF index and C-peptide were lower in PA patients compared with EH controls, with a significantly reduced first-phase insulin secretion during intravenous glucose tolerance test [22, 32] . PA patients were also found to have a higher rate of insulin resistance, as evidenced by a higher HOMA-index [40] , lower glucose disposal rate, decreased tissue insulin sensitivity index, and lower metabolic clearance rate of glucose [28] . The observation that adrenalectomy, which leads to the removal of elevated aldosterone, was associated with significantly better improvement in glucose metabolism compared with MRA therapy, which only antagonizes mineralocorticoid receptors without attenuating hyperaldosteronism, further supports this theory.
It is also postulated that mineralocorticoid receptors have high affinity to glucocorticoids which lead to inflammation and insulin resistance through their activation [41] . This could be contributed to in part by the presence of hypokalemia which can decrease the insulin secretion through the ATP-sensitive potassium channels found on the surface of pancreatic islet cells [42] . Hypomagnesemia, on the other hand, is associated with insulin resistance in patients with type 2 diabetes [43] . As aldosterone induces the renal magnesium loss leading to hypomagnesemia [44, 45] , it is, thus, not surprising that hyperaldosteronism is associated with insulin resistance through similar pathways as patients with type 2 diabetes [46] .
Another possibility that might contribute to the occurrence of DM is the association of PA with autonomous cortisol secretion. Akehi et al. found non-suppressed 1 mg-overnight dexamethasone suppression cortisol levels in a diabetic PA population [26] . This was echoed by a study from Germany, which showed 77.6% of the PA cohort having a pathological response in at least one out of three Cushing screening tests performed. There was a significantly higher 2 h plasma glucose post 75 g oral glucose tolerance test with higher prevalence of type 2 diabetes among PA patients who exhibited a pathological response to the 1mg-overnight dexamethasone suppression test [47] . The presence of glucocorticoid excess is independent of PA subtype or tumor tissue genotypes, and is similar to that found in subclinical Cushing's syndrome, who are known to suffer from increased cardiovascular risks [46, 48] . Almost a third of patients, following the surgical removal of APA, failed a co-syntropin test, which would be in keeping with preoperative cortisol excess leading to contralateral adrenal insufficiency postoperatively [20] .
Aldosterone is also postulated to impair insulin secretion and increase insulin resistance by several other mechanisms [49] . Aldosterone impairs glucose uptake into the liver via the reduction of GLUT2 expression in the liver [50] , and increases the expression of glucose-6-phosphatase responsible for hepatic glucose release in a dose-dependent manner [51] , which explain elevated fasting plasma glucose levels seen in PA patients. These were markedly attenuated by the treatment with MRA [52, 53] . In addition, by decreasing GLUT4 expression in the skeletal muscle and adipocytes, aldosterone impairs glucose uptake in a dosedependent manner [50] . Aldosterone also enhances insulinlike growth factor-1 (IGF-1) signaling followed by the increasing IGF-1 receptor expression in vascular smooth muscle cells via the activation of mineralocorticoid receptors and Scr-kinase [54] , which is related to higher risk of developing DM in the next 5 years [55] . The schematic diagram summarizing the possible associations is shown in Fig. 1 Associations between primary aldosteronism and diabetes, poor bone health, and sleep apnea-what do we. . .
PA and OSA

Human observations
In a cross-sectional study examining 114 subjects referred for resistant hypertension, 63.2% were found to have high probability of having sleep apnea based on their responses to the Berlin Questionnaire, with greater 24-h urinary aldosterone excretion (13.6 ± 9.6 µg vs 9.8 ± 7.6 µg, p < 0.05) compared with subjects at low risk of sleep apnea, although the level of serum PRA (1.2 ± 1.8 ng/ml/h vs 1.9 4.1 ng/ml/h) and serum aldosterone (13.7 ± 9.0 vs 13.5 ± 8.8 ng/dL) were not statistically different [56] . The same group of researchers also found an OSA prevalence of 84% among patients with hyperaldosteronism compared with 77% among those without, despite no difference in BMI and neck circumference. The plasma aldosterone concentration (PAC) and 24-h urinary aldosterone excretion were noted to be significantly correlated with the apneahypopnea index (AHI) in the high-aldosterone group with no correlation seen in the normal-aldosterone group [57] . Several other studies also reported a high prevalence of OSA among subjects with resistant hypertension, ranging between 82.2-92.3% [58] [59] [60] . These subjects had higher PAC [58, 59, 61] and 24h-urinary aldosterone levels [59] , with a positive correlation between PAC and 24h-urinary aldosterone level with AHI [58, 59] . Similarly, Murro et al. reported high prevalence of PA among subjects with hypertension and OSA, with positive correlation between PRA levels and AHI (r = 0.35, p < 0.01) [62] .
In contrast, in a cross-sectional study of 422 resistant hypertensive patients of whom 82.2% had OSA, no differences in plasma aldosterone or renin activity were noted when compared with those with mild/no OSA [60] . In addition, two other studies which examined levels of serum aldosterone and renin among 21 subjects (AHI > 15) [63] and 19 subjects (AHI > 10) [64] respectively with OSA but without hypertension, compared with closely-matched healthy non-OSA subjects, found no difference in the serum aldosterone and renin levels between the two groups.
Effect of treatment
Following 8 weeks of treatment with Spironolactone, AHI (39.8 ± 19.5 vs 22.0 ± 6.8 events/hr, p < 0.05) and hypoxic index (13.6 ± 10.8 vs 6.7 ± 6.6 events/hr, p < 0.05) were significantly reduced in 12 subjects with resistant hypertension and OSA [65] . In a separate study, 30 patients with resistant hypertension and moderate-to-severe OSA given spironolactone had a significant reduction in oxygen desaturation index (20.8 ± 15.0 vs 0.3 ± 16.1, p < 0.05) as well as from improvement in AHI and hypopnea index [66] . Three months of eplerenone resulted in similar improvements in patients with resistant hypertension and OSA, along with reduction in the neck circumference and BP [67] .
This effect does not seem to differ between treatment modality. The mean Berlin score showed a significant reduction in subjects who underwent adrenalectomy (1.69 vs 1.33, p < 0.001) and those who received medical therapy, but not specific to MRA, (1.57 vs 1.37, p = 0.03), with no significant change in BMI, demonstrating a reduced probability of OSA in both groups post treatment [68] . Although not statistically significant, likely due to the small sample size, Wolley et al. showed an improvement in AHI for both groups of patients who underwent adrenalectomy (p = 0.11) and those who received Spironolactone (p = 0.2) [69] .
On the other hand, CPAP treatment of 1-12 months, with good adherence, led to a significant improvement in the serum aldosterone and BP, with the downregulation of renal RAS activity in subjects with OSA [61, [70] [71] [72] , although an immediate effect was not seen with short duration, overnight use of CPAP therapy in normotensive patients with OSA [63] .
Summary: As both OSA and hyperaldosteronism lead to the increased cardiovascular morbidity and mortality, the two conditions require prompt diagnoses and treatment. It is essential to screen all hypertensive patients affected by OSA for the presence of PA [1] . PA-directed therapy leads to an improvement in OSA severity. Similarly, CPAP treatment with good adherence can improve BP with the downregulation of the renal RAS activity in patients with OSA.
Proposed mechanism
The link between aldosterone and OSA could be bidirectional. Aldosterone causes salt and water retention leading to edema of the parapharyngeal tissues resulting in the obstruction of upper airway and worsening of OSA symptoms [73] . Intensified diuretic therapy using metolazone and spironolactone for 14 days led to significant improvements in AHI and neck circumference [74] . However, it is difficult to judge at this stage, if the effect of MRA is solely targeted at the deleterious effects of aldosterone or at the reduction of fluid retention via its diuretic effect. Moreover, MRA use could also implicate cortisol as well as other mineralocorticoid hormones, of which more studies are needed to elucidate these relationships.
On the other hand, patients with OSA are found to have high levels of circulating reactive oxidative species, which contribute to the oxidative stress [75] . This leads to the impairment of nitric oxide bioactivity as well as the activation of the inflammatory cascade, leading to endothelial dysfunction, which could also be worsened by elevated levels of aldosterone, ultimately leading to hypertension, as well as the determination of future vascular complications [76, 77] .
Another proposed mechanism is the stimulation of the baroreceptors in patients with OSA due to intermittent hypoxia, which leads to increased sympathetic activity and increased catecholamine release [78] . This causes increased vascular resistance, increased heart rate, and cardiac output with stimulation of the RAAS, leading to elevated BP [79, 80] .
The intermittent surges of sympathetic nerve activity in subjects with OSA may also be responsible in the direct effect of a rise in BP and heart rate during times of obstructive apnea [81] . Renal sympathetic denervation in an animal model of OSA abolished post-apneic BP rises, implicating an interaction between the sympathetic activity, OSA, and resistant hypertension [82] . The schematic diagram summarizing the possible associations is shown in Fig. 2 .
PA and bone health
PA and bone profile
In three small studies patients with PA were found to have higher serum parathyroid hormone (PTH) levels compared with EH patients and normotensive healthy subjects [83] [84] [85] , with no significant difference in urinary calcium excretion [83, 84] . Although there were inconsistent results with respect to total serum calcium levels among these studies, studies of larger sample size confirmed elevated PTH levels and urinary calcium excretion, with lower serum total calcium concentrations in PA patients [86] [87] [88] . Another study also found higher PTH levels (9.8 vs 5.3 pmol/L, p < 0.01) and urinary calcium excretion (6.28 ± 1.85 vs 4.28 ± 1.18 mmol/d, p < 0.01) among subjects with PA compared with those with nonfunctioning adrenal adenoma [89] . Although the majority of the studies demonstrated deficient 25OH-vitamin D levels among patients with PA, a recent meta-analysis showed no significant differences in these levels when compared with EH or healthy subjects [90] .
The findings of elevated PTH, increased urinary calcium excretion, and low serum total calcium levels in PA led to concerns of bone loss with hyperaldosteronism. Bone turnover markers were assessed in two studies. Ceccoli et al. showed a nonsignificant elevated serum CTX-1 [86] , whereas Loh et al. found a significantly higher serum CTX (0.406 vs 0.277 ng/mL, p = 0.005) and serum P1NP (42.59 vs 33.95 ng/mL, p = 0.045) among those with PA compared with EH [85] .
PA and osteoporosis
Although no significant differences were found in bone mineral density (BMD) measurements at lumbar spine, femoral neck, total neck, and distal radius between patients with PA and EH or healthy subjects, a higher prevalence of osteoporosis was found in subjects with PA, when compared with EH (10.5 vs 4%) [87] , non-PA adrenal incidentaloma (72.7 vs 20.0%) [89] , and normotensive healthy subjects (10.5 vs 5%) [87] . Notsu [91] . This risk seems to be even higher when compared with nonfunctioning adrenal incidentaloma (OR 15.4; 95% CI 1.83-130, p = 0.012) [89] . A large cohort database study of 2533 patients with PA in Taiwan found a higher risk of fracture at any site (OR 1.83; 95% CI 1.55-2.15, p < 0.001) compared with EH controls [92] . The incidence of fracture at any site was estimated to be 14.4 per 1000 person-years for PA compared with 8.3 per 1000 person-years for EH [92] .
Effect of treatment
Since aldosterone is believed to cause an increased urinary calcium excretion leading to bone loss, the effect of PA treatment in improving bone metabolism was tested in several studies. After a mean of 24 ± 6 months following PA-directed treatment, a significant reduction in serum PTH was reported (81.7 ± 33.8 to 63.1 ± 20.7 pg/mL, p < 0.05) [86] . This reduction was noted as early as 3 months post treatment, either with adrenalectomy or MRA therapy (38.54-31.11 pg/mL, p = 0.041) [85] . Loh et al. also showed a significant reduction in bone turnover markers (serum CTX reduced by 20%, p = 0.012, serum P1NP reduced by 18%, p = 0.036), signifying improved bone strength, which may subsequently translate to reduced fracture risk, as high bone turnover is associated with lower BMD [85, 93] . Significant improvements in the Z-scores for lumbar spine, femoral neck, and total neck on BMD were seen 1-2 years post PA treatment. There seems to be no difference with regards to treatment modality as both adrenalectomy and MRA led to improvement of these markers. Jiang et al. found significant reduction in the serum PTH (9.9-5.2 pmol/L, p < 0.001 vs 11.7-6.3 pmol/L, p < 0.001) and urinary calcium excretion (5.0-2.4 mmol/24 h, p < 0.001, vs 4.7 to 2.6 mmol/24 h, p < 0.001), with an increment in the serum total calcium (2.16-2.34, p < 0.001 vs 2.18-2.24 mmol/L, p < 0.05) for both modalities of treatment [88] . Although studies on the effect of MRA therapy on reduction of fractures among patients with PA are not available to-date, spironolactone was found to be inversely associated with total fractures among men with congestive heart failure, a condition characterized by the activation of the RAAS leading to elevated aldosterone levels, providing further evidence for a beneficial effect of spironolactone on bone health [94] .
Summary: At present, many studies have consistently shown an elevated PTH level among subjects with PA, compared with normal subjects, patients with EH and those with nonfunctioning adrenal incidentaloma. Subjects with PA have a higher prevalence of osteoporosis as well as fractures. PA-directed treatment lead to the improvement in PTH, bone markers, as well as BMD. Since adrenalectomy removes excess aldosterone and MRA therapy antagonizes aldosterone receptor binding as well as decreasing calcium and magnesium excretion, it is not surprising that both modalities of treatment lead to important skeletal benefits.
Proposed mechanism
Many studies have observed a positive link between aldosterone excess and hyperparathyroidism. The relationship between PTH and aldosterone is likely bidirectional. Elevated aldosterone is observed in patients with primary hyperparathyroidism, which is attenuated with parathyroidectomy [95] [96] [97] [98] [99] . On the other hand, elevated PTH is consistently seen in all studies of patients with PA.
Aldosterone excess in the chronic state leads to excess fecal and urine calcium excretion causing hypocalcemia, which then leads to secondary hyperparathyroidism. This further causes an increased reabsorption of calcium from the gastrointestinal tract, bones, and kidneys [100] . Populationbased studies revealed higher serum PTH concentrations even among healthy subjects with aldosterone and ARR in the highest compared with the lowest quartile [101, 102] . Healthy volunteers who received angiotensin II infusion demonstrated an increase in intact PTH likely due to a decrease in ionized serum calcium [103] . Healthy subjects without PA given spironolactone for 6 weeks showed a significant reduction in serum PTH with a concurrent increment in serum calcium compared with subjects who were given placebo [104] . Adrenalectomy also corrected the elevated PTH levels in patients with APA. These observations further strengthen the interaction between the RAAS and PTH.
Another explanation is the co-existence of PTH receptors in the adrenal gland and mineralocorticoid receptors in the parathyroid gland. PTH-receptor type 1 is found in APA tissues as well as the zona glomerulosa of normal adrenal glands [105] . PTH infusion caused a significant rise in urinary tetrahydroaldosterone excretion along with a rise in BP and serum calcium level [106] . This is likely due to the activation of PTH-PTH-RP receptors within zona glomerulosa cells of the adrenal glands, leading to increased aldosterone secretion [107] . On the other hand, mineralocorticoid receptor messenger RNA and protein are elevated in the nuclei of parathyroid adenoma cells [108] . Aldosterone excess can thus directly stimulate these receptors found on the parathyroid gland, leading to elevated PTH, although acutely, this effect seems to be accentuated by angiotensin II rather than aldosterone [103] . Removal of the PTH-secreting adenoma led to a fall in BP, thereby supporting the existence of this relationship [96] . This is further evidenced by a reduction in PTH levels seen with PA-directed therapy, with removal of aldosterone via adrenalectomy or blockade of mineralocorticoid receptors via MRA.
The role of vitamin D in PA, on the other hand, is less well-established [109] . Vitamin D receptors have been found in adrenocortical tissues [110] . 1,25-(OH)2 D3 has also been reported to decrease expression and activity of CYP21A2, the gene encoding the 21-hydroxylase enzyme required for glucocorticoid and mineralocorticoid synthesis [111] . Despite these findings, little is known regarding the role of vitamin D in adrenal hormone secretion [112] . The finding of PTH-receptor type 1 in APA tissues may also suggest a possible effect of vitamin D on these receptors regulating PTH secretion [105] . As vitamin D deficiency is closely-linked to the presence of osteoporosis, hypovitaminosis D could also contribute to the presence of lower bone mass in patients with PA, although no significant differences in vitamin D levels were found when compared with EH or healthy subjects [90] . The schematic diagram summarizing the possible associations is shown in Fig. 3 .
Hyperparathyroidism affects mainly cortical bone strength rather than cancellous bone. Subjects with PA were shown to have higher rates of vertebral fractures. Thus, whether or not osteoporosis seen in patients with PA is contributed by non-PTH related mechanisms, remains undetermined and warrants further large scale trials.
Conclusion
This present review aimed to collect and put into perspective current available research regarding the nonclassical associations between PA and DM, OSA and osteoporosis. It focused on the potential relationships between PA and these entities, and presented evidence for potential causal links and mechanisms. Current evidence has suggested that PA manifests across a wide spectrum of diseases. Given that clear relationships between PA and these conditions have yet to be established, there is a need for further studies to examine these links, particularly the direct effects of the aldosterone excess on glucose metabolism, OSA and bone health, as well as comparing effects of different classes of antihypertensive drugs on these conditions. Long-standing, undiagnosed PA frequently leads to aldosterone-specific morbidity and mortality. The evidence presented herein further underscores the necessity of early recognition and diagnosis of PA, as well as the need for early and appropriate treatment in order to reduce the multiple adverse sequelae related to an untreated PA.
Author contributions HHL conceived and designed the work that led to the submission, acquired data, and interpreted the results. HHL drafted the manuscript while NS revised the manuscript. Both authors approved the final version and agree to be accountable for all aspects of the work. Associations between primary aldosteronism and diabetes, poor bone health, and sleep apnea-what do we. . .
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of interest.
Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
